

## *Have we already known what is the most appropriate approach of PARPi in frontline OC therapy?*

Date: May 27<sup>th</sup> (Friday)

Time: 20:00-21:30 [GMT+8]



**Prof. Jonathan A Ledermann**  
University College London, UK



**Prof. Nicoletta Colombo**  
University of Milan-Bicocca, Milan, Italy.



**Dr. Chih-Long Chang,**  
Mackay Memorial Hospital, Taiwan



**Dr. Wen-Shiung Liou**  
Kaohsiung Veterans General Hospital, Taiwan

Time [GMT+8]	Topic	Speaker
20:00-20:20	Introduction & Overview the current treatment landscape	Dr. Chih-Long Chang Dr. Wen-Shiung Liou
20:20 -20:50	<b>Time elapsed - Is PARPi widely used at present time in frontline ovarian cancer therapy?</b>  <b>[Debate] Have we already known what is the most appropriate approach?</b> <b><u>Monotherapy vs Combination therapy</u></b>	Prof. Jonathan A Ledermann Prof. Nicoletta Colombo
20:50 -21:10	<b>Rebuttal on Debate</b>	Prof. Jonathan A Ledermann Prof. Nicoletta Colombo Dr. Chih-Long Chang Dr. Wen-Shiung Liou
21:10 -21:25	<b>Discussion &amp; QA</b>	Prof. Jonathan A Ledermann Prof. Nicoletta Colombo Dr. Chih-Long Chang (Chair) Dr. Wen-Shiung Liou (Chair)
21:25 -21:30	<b>Closing</b>	Dr. Chih-Long Chang

**\*\* 本會議將會提供學分認證，需事先報名 \*\***

**\*\*This is an AstraZeneca organized non-promotional meeting. For Healthcare Professionals only.\*\***

主辦單位: 臺灣阿斯特捷利康股份有限公司

協辦單位:



台灣婦癌醫學會



中華民國婦癌醫學會  
Society of Gynecologic Oncology, Republic of China



台灣婦產科醫學會  
Taiwan Association of Obstetrics and Gynecology